# Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy

> **NCT02948998** · PHASE4 · UNKNOWN · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 260 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy
- Fibrosis

## Interventions

- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT02948998
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-14
- **Primary completion:** 2019-10
- **Final completion:** 2020-07
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2018-05-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948998, "Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02948998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*